Stergiou George S, Makris Thomas, Papavasiliou Maria, Efstathiou Stamatis, Manolis Athanasios
Hypertension Centre, Third University Department of Medicine, Sotiria Hospital, Athens, Greece.
J Hypertens. 2005 Apr;23(4):883-9. doi: 10.1097/01.hjh.0000163159.22116.ab.
To compare the additional antihypertensive effects of an angiotensin-converting enzyme inhibitor (ACEI), a dihydropyridine calcium antagonist and a diuretic in patients whose hypertension is not controlled by full-dose angiotensin receptor blocker (ARB) monotherapy.
Individuals with an ambulatory blood pressure (ABP) that was not controlled by valsartan 160 mg once daily were allocated randomly to two groups: those in group A (n = 35) were assigned randomly to treatment with benazepril 20 mg once daily or chlorthalidone 12.5 mg once daily, whereas patients in group B (n = 29) were assigned randomly to benazepril 20 mg once daily or amlodipine 5 mg once daily. All individuals continued to receive background valsartan 160 mg once daily. After 5 weeks, patients crossed over to the alternative valsartan-based combination treatment of each group for a second 5-week period. Twenty-four-hour ABP monitoring was performed before the random allocation to groups and at the end of each randomized combination pharmacotherapy period.
Sixty-four individuals completed the study: 32 men and 32 women (mean +/- SD age 48.2 +/- 7.9 years, average 24-h ABP on valsartan monotherapy 143.4 +/- 12.6/87.7 +/- 7.8 mmHg). Significant additional antihypertensive effects on the average 24-h ABP were obtained with benazepril (8.6 +/- 8.8/6.3 +/- 6.7 mmHg), amlodipine (15.2 +/- 12.9/9.9 +/- 6.8 mmHg) and chlorthalidone (13.5 +/- 11.6/9.5 +/- 7.7 mmHg) (P < 0.001 for all additional antihypertensive effects). The additional effects of amlodipine and chlorthalidone added to valsartan were approximately 6/3.5 mmHg (P < 0.05) greater than that of benazepril.
In patients in whom hypertension was not controlled by full-dose ARB monotherapy, a diuretic, a calcium antagonist or an ACE inhibitor provided significant additional antihypertensive effect. The antihypertensive effects of the ARB-diuretic and the ARB-calcium antagonist combinations were superior to that of the ARB-ACE inhibitor combination.
比较血管紧张素转换酶抑制剂(ACEI)、二氢吡啶类钙拮抗剂和利尿剂对接受全剂量血管紧张素受体阻滞剂(ARB)单药治疗但高血压未得到控制的患者的额外降压效果。
将每日一次服用160 mg缬沙坦但动态血压(ABP)未得到控制的个体随机分为两组:A组(n = 35)随机分配接受每日一次20 mg苯那普利或每日一次12.5 mg氯噻酮治疗,而B组(n = 29)随机分配接受每日一次20 mg苯那普利或每日一次5 mg氨氯地平治疗。所有个体继续每日一次接受基础剂量160 mg缬沙坦治疗。5周后,患者交叉接受每组基于缬沙坦的替代联合治疗,为期5周。在随机分组前以及每个随机联合药物治疗期结束时进行24小时ABP监测。
64名个体完成了研究:32名男性和32名女性(平均±标准差年龄48.2±7.9岁,缬沙坦单药治疗时平均24小时ABP为143.4±12.6/87.7±7.8 mmHg)。苯那普利(8.6±8.8/6.3±6.7 mmHg)、氨氯地平(15.2±12.9/9.9±6.8 mmHg)和氯噻酮(13.5±11.6/9.5±7.7 mmHg)对平均24小时ABP均有显著的额外降压效果(所有额外降压效果P < 0.001)。氨氯地平和氯噻酮加至缬沙坦后的额外效果比苯那普利大约高6/3.5 mmHg(P < 0.05)。
在接受全剂量ARB单药治疗但高血压未得到控制的患者中,利尿剂、钙拮抗剂或ACE抑制剂可提供显著额外降压效果。ARB - 利尿剂和ARB - 钙拮抗剂联合用药的降压效果优于ARB - ACE抑制剂联合用药。